Introduction {#s0005}
============

Prostaglandin F~2α~ (PGF~2α~) is an arachidonate biosynthetic pathway end-product, which rate-limiting step is catalyzed by cyclooxygenases (COX), enzymes implicated in various disease states including cancer [@b0005]. PGF~2α~ has been scarcely studied on cancer although it has been detected in several tumor types and cancer patient body fluids [@b0010], [@b0015], [@b0020], recently has been mechanistically associated with colon cancer progression [@b0025].

Previous studies have shown increases of COX, prostaglandin synthases, prostaglandins and receptors in epithelial ovarian cancer (EOC) [@b0030], [@b0035]. EOC, which comprises 90% of all ovarian malignancies, is the leading cause of death from gynecological cancer, due to late diagnosis, in developed countries [@b0040], [@b0045].

PMEPA1 gene expression has been found in several primary and metastatic tumor types [@b0050], [@b0055], [@b0060]. Depending on the tumor tissue origin, PMEPA1 has been shown to have a pro-tumor or anti-metastatic role. Thus, in prostate cancer, it is well established as a part of a negative feedback loop of the Androgen Receptor (AR), which induces PMEPA1, that participates in the degradation of the receptor through an E3 ubiquitin ligase complex [@b0065]. Depending on whether the prostate cancer cells are positive or negative to AR, PMEPA1 has a growth inhibitory or a growth-promoting role [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], while some studies have shown that it inhibits prostate cancer metastases to bone [@b0070]. On the other hand, PMEPA1 has been already shown to have pro-tumorigenic effects y breast and lung cancer [@b0090], [@b0095], [@b0100], [@b0105] and high expression levels in other types, such as kidney and colorectal cancer [@b0050], [@b0110], [@b0115]. *PMEPA1* can also be induced by transforming growth factor-β (TGF-β) [@b0050]. PMEPA1 downregulates TGF-β signaling by sequestering R-SMAD and promoting lysosomal degradation of TGF-β receptor [@b0120]. PMEPA1, through a negative feedback loop, is described to switch TGF-β from tumor suppressor to tumor promoter in breast cancer [@b0060]. In addition, TGF-β-dependent growth of aggressive breast cancer has been suggested to depend on increased expression of *PMEPA1* gene [@b0055]. TGF-β has been implicated in physiological and pathological processes in the ovary [@b0125], [@b0130]. In ovarian cancer, TGF-β has been shown to control cell proliferation [@b0135].

Here, we identify, *PMEPA1* as a COX2/PGF~2α~ up-regulated gene through the induction of TGF-β and we have deciphered its role in ovarian cancer progression. We have found that PGF~2α~ induced *TGFB1* and *PMEPA1* and we provide new evidence of its important role in ovarian cancer progression. Moreover, our results indicate that PMEPA1 is a critical regulator of epithelial plasticity, conferring a growth advantage in ovarian cancer cells.

Materials and methods {#s0010}
=====================

Ovarian samples {#s0015}
---------------

A series of 19 normal, 51 primary tumors and 37 metastatic/relapse ovarian samples were collected at the MD Anderson Cancer Center Biobank (Madrid; record number B.0000745, ISCIII National Biobank Record), the center's ethical committee approved the study, and a complete written informed consent was obtained from all patients. The sample characterization was performed by a pathologist (ARS), who determined the histological cancer subtype according to the World Health Organization (WHO) criteria [@b0140], and the stage and grade ([Supplemental Table 1](#s0105){ref-type="sec"}).

Cell lines {#s0020}
----------

SKOV3-lucD6 cells, stably expressing Firefly Luciferase, were obtained from Caliper Life Sciences. SKOV3 and TOV112D cells were from ATCC and A2780 cell line was provided by Sigma-Aldrich. OVCAR8 cell line was a gift from Dr. JM Cuezva (CBMSO). All cell lines were grown in the recommended conditions.

Reagents {#s0025}
--------

All generic reagents were from Invitrogen or Sigma-Aldrich. Oligonucleotide and antibody details can be found in [Supplementary Tables 2 and 3](#s0105){ref-type="sec"}. Plasmids and Lentiviral vector transduction methods are listed in [Supplementary Material](#s0105){ref-type="sec"}s and Methods.

Cell assays {#s0030}
-----------

Cell proliferation assays were performed plating 20,000 cells in various 35 mm wells and each day of the experiment cells from a different well were counted. Growth was also quantified by Crystal Violet staining: Glutaraldehyde fixed cells were stained with 0.5% Crystal Violet/50% methanol for 20'. Stain was dissolved in 10% Acetic Acid after washing and O.D. measured at 570 nm.

Substrate independent cell growth assays were performed by seeding 50,000 cells/well in ultra-low attachment surface 24-well plates (Costar) in normal growth medium. At the end of the experiment relative cell numbers were estimated by Alamar Blue staining (Invitrogen).

RNA isolation and RT-qPCR analysis were performed as described [@b0025].

Immunofluorescence and Western blotting were performed as described before [@b0025]. Images were taken using a Zeiss Axioscop2 plus with a color CCD camera or the Zeiss LSM710 confocal microscope. For nuclear/cytoplasmic/membrane fractionation please see [Supplemental Methods](#s0105){ref-type="sec"}. For WB, densitometry quantification of the bands obtained is included in [Supplementary Figures S6 and S8](#s0105){ref-type="sec"}.

Luciferase assays were performed as described before [@b0025].

Tumor growth in nude mice {#s0035}
-------------------------

In all cases, the minimum cell number indicated for each xenograft model was used. In the case of A2780 and TOV122D cell lines, 10^6^ and 5x10^4^ cells were injected subcutaneously in 6 week old female Rag2/Il2rg Double Knockout mice (R2G2, ENVIGO, France). For the SKOV3-Luc subcutaneous and intraperitoneal xenograft models, 6-week-old female Swiss Nude mice (Crl:NU (Ico)-Foxn1^nu^, Charles River Laboratories) were injected with 1X10^6^ cells, following the instructions of the provider of the cells, Caliper LS. Mice were weighted once a week and the tumor volume was estimated with a digital caliper by measuring: length × width × height. Tumor growth estimation was made as described before [@b0025], [@b0145] using a Xenogen IVIS® Lumina CCD camera (Caliper Life Sciences). In the orthotopic mouse model of ovarian cancer, animals were injected with 5x10^5^ in the left ovary.

Histological analysis and immunohistochemistry {#s0040}
----------------------------------------------

Tumors from mice and patients were fixed in 4% phosphate buffered formalin (pH 7.4) and 2 µm paraffin-embedded sections were immunostained, performed as previously described [@b0025], [@b0145]. Antibodies used for immunohistochemistry: anti-PMEPA1 (1:50) as primary antibody (Sigma-Aldrich) and secondary antibody conjugated with HRP (Envision + Dual link System HRP, Dako). Finally, sections were developed using DAB solution (Liquid DAB + substrate chromogen system, DAKO K3468) and images were taken with a LEICA DMD108 Digital Microimaging Device (Leica Microsystems).

Databases and genomics analysis was performed through the UCSC Xena Browser as indicated in [Supplemental Methods](#s0105){ref-type="sec"}.

Statistical analysis {#s0045}
--------------------

Results are expressed as mean ± SEM. The Student's t test, the ANOVA test or Welch's t-test were used for comparisons, where necessary. \*p \< 0.05 and \*\*p \< 0.01 denote statistical significance. For gene expression correlation/covariance, Pearson's correlation coefficient was calculated. The statistical analysis was performed using the GraphPad Prism 4.0 statistical software.

Results {#s0050}
=======

TGFB1 expression correlates with the COX2/PGF~2α~ /NFAT pathway {#s0055}
---------------------------------------------------------------

TGF-β is a crucial factor for ovarian homeostasis and tumorigenesis [@b0135]. Indeed, gene expression analysis of the TCGA TARGET GTEx patient cohort RNA sequencing data using the UCSC XENA cancer browser shows a 2-fold increase of TGFB1 mRNA levels in ovarian tumor samples, compared to normal ovarian tissue ([Supplementary Figure S1](#s0105){ref-type="sec"}A). PGF~2α~ has an important role in the female reproductive system and is known to be produced in the ovary, as is produced also in ovarian tumors [@b0035]. PGF~2α~ binds and signals through the F prostaglandin receptor (FP, *PTGFR*), a G protein coupled receptor, coupling mainly to Gq, thus leading to an increase in intracellular Ca^2+^ levels [@b0150]. Consequently, PGF~2α~ binding to FP causes Ca^2+^/calcineurin activation NFAT transcription factors, implicated in a growing variety of physiological and pathological functions, including cancer [@b0155]. Interestingly, we found that PGF~2α~ significantly increased *TGFB1* mRNA levels in ovarian serous adenocarcinoma SKOV3 cells ([Suppl. Figure S1](#s0105){ref-type="sec"}B). *TGFB1* mRNA levels correlated to the *PTGS2* (Pearson's r = 0.20, p \< 0.0001, n = 369) and *PTGFR* mRNA levels in ovarian tumors ([Suppl. Figure S1](#s0105){ref-type="sec"}C). On the other hand, the calcineurin/NFAT activator Ca^2+^ ionophore A23287 significantly increased *TGFB1* mRNA levels in SKOV3 cells mimicking the PGF~2α~ effect ([Suppl. Figure S1](#s0105){ref-type="sec"}B). We found that *NFATC2* is up-regulated more than 2 fold in ovarian tumors, compared to healthy tissue ([Suppl. Figure S1](#s0105){ref-type="sec"}D). Moreover, *NFATC2* and *TGFB1* mRNA levels correlated strongly ([Suppl. Figure S1](#s0105){ref-type="sec"}E), as did also *NFATC1* and *TGFB1* (Pearson's rho = 0.41, p \< 0.0001, n = 369). As expected, TGFB1 levels also correlated with the *RCAN1 levels* (a *bona-fide* NFAT transcriptional target) mRNA levels ([Suppl. Figure S1](#s0105){ref-type="sec"}F).

Along these lines, multiple NFATc1 binding sites were identified in the promoter region of TGFB1, using chromatin immunoprecipitation and mass sequencing (ChIP-seq) data experimental from the Gene Transcription Regulation Database (GTRD), two of them in the *TGFB1* gene regulatory region located in its first intron ([Suppl. Figure S2](#s0105){ref-type="sec"}), Site IDs: 34541886--7, indicating a possible transcriptional regulation of TGFB1 by PGF~2α~/NFAT signaling. All these findings could indicate a close relationship between the COX-2/PGF~2α~/FP/Ca^2+^/NFAT pathway and TGFB1.

PMEPA1 levels are elevated in patients' ovarian tumor samples {#s0060}
-------------------------------------------------------------

PMEPA1 has been proposed as a TGF-β -induced gene [@b0060]. Indeed, we found a strong correlation between TGFB1 and PMEPA1 mRNA levels in the TCGA ovarian cancer cohort ([Suppl. Figure S1](#s0105){ref-type="sec"}G). A similar correlation was found between PMEPA1 and RCAN1 mRNA levels ([Suppl. Figure S1](#s0105){ref-type="sec"}H), indicating the possible, direct or indirect, implication of NFAT in the PMEPA1 gene expression. Additionally, we found tumor PMEPA1 mRNA levels to be significantly higher than in normal ovary ([Suppl. Figure S1](#s0105){ref-type="sec"}I).

To confirm this, we performed immunohistochemistry on normal tissue obtained from ovaries, as well as ovarian primary tumors and relapses. Primary ovarian tumors showed strong PMEPA1 staining in tumor cells compared to normal ovaries that showed diffuse expression in some epithelial cells ([Figure 1](#f0005){ref-type="fig"}).Figure 1PMEPA1 expression is widely expressed in ovarian cancer. Representative images of PMEPA1 (top), E-cadherin (middle), and beta-catenin (down) expression by immunohistochemistry in normal A, and primary ovarian tumors B. Magnification 40x, inset 63x. The magnification areas are highlighted in the square. C. Quantitative analysis of PMEPA expression in normal, primary tumor and metastasis/relapse ovarian samples. The significance of the differences observed between the different groups was determined with a Chi-Square test P \< 0.0001.

The patient cohort used for determining PMEPA1 protein levels includes only high-grade tumors and most of them resulted positive for PMEPA1. Thus, no significant differences in patient survival according to PMEPA1 expression could be obtained. However, after analysis of the gene expression databases available (TCGA ovarian cancer), high PMEPA1 expression associated with lower survival probability ([Suppl. Figure S3](#s0105){ref-type="sec"}). The above observations suggest PMEPA1 could have an important role in ovarian cancer progression and it could be considered as a potential biomarker for ovarian tumor characterization and patient stratification.

Induction of PMEPA1 expression by PGF~2α~ {#s0065}
-----------------------------------------

Treatment of SKOV3, OVCAR8, TOV112D or A2780 ovarian cancer cells with fluprostenol, a metabolically stable PGF~2α~ analog, increased PMEPA1 mRNA levels, as did TGF-β treatment. The combination of both treatments had a partially additive effect ([Figure 2](#f0010){ref-type="fig"}A). We transduced Skov3 cells with lentiviral shRNA vectors to knockdown *PTGFR* mRNA, thus decreasing PTGFR levels and signaling. When the resulting cell lines were treated with PGF~2α~ ([Figure 2](#f0010){ref-type="fig"}B) or fluprostenol (not shown) they failed to increase PMEPA1 mRNA levels as the control scrambled shRNA cells did, indicating that PMEPA1 induction depended on the PGF~2α~ signaling. Moreover, calcineurin/NFAT inhibition by cyclosporine A (CSA) could revert PGF~2α~-induced TGFB1 and PMEPA1 increase ([Figure 2](#f0010){ref-type="fig"}C). Indeed, CSA not only reverted significantly both genes induction, but also reduced their levels in the absence of PGF~2α~, indicating a possible basal Ca^2+^/calcineurin signaling. Interestingly, the PTGFR induction of *PMEPA1,* but not *RCAN1*, a direct NFAT target, was reverted by co-treatment with an inhibitor of TGF-β type I receptor, LY2109761 ([Figure 2](#f0010){ref-type="fig"}D), indicating that basal TGFβR signaling may be necessary for basal and Ca^2+^ stimulated PMEPA1 expression.Figure 2PMEPA1 is upregulated by cooperative action of TGFβ and PGF~2α~. A. PMEPA1 mRNA levels quantification in the cells indicated after 24 h of treatment with vehicle (CT), 1 µM fluprostenol (flup), 5 ng/ml TGFβ, and the combination of the two (Flup + TGF). B. PMEPA1 and PTGFR mRNA levels quantification in SKOV3 derived cell lines stably expressing a scrambled shRNA (scr) or three PTGFR specific shRNAs (FP19, FP55, FP86) after 24 h of treatment with vehicle (CT) or 1 µM PGF~2α~. Only scr cells were able to significantly increase (\*: p \< 0.05) PMEPA1 mRNA with PGF~2α~ treatment. C. PMEPA1, TGFB1 and RCAN1 mRNA levels quantification in SKOV3 cells after 24 h of treatment with vehicle (CT), 1 µM PGF~2α~, 100 ng/ml cyclosporine A (CSA) or combination of the two. CSA significantly reduced the levels of the three genes below the control levels (p \< 0.05). PGF~2α~ significantly increased the three genes' levels, while the combination of the two reduced the levels of the three genes, although in the case of TGFB1, the levels were significantly different from CT as well as from PGF~2α~. D. PMEPA1 and RCAN1 mRNA levels quantification in SKOV3 cells after 24 h of treatment with vehicle (CT), 1 µM Flup, 1 mM A23187 Ca^2+^ ionophore (IO), 10 µM LY2109761 (LY) or combinations. Both genes are induced by Flup or IO (p \< 0.05). LY treatment only affects PMEPA1 levels reducing them below CT levels, even in combined treatments (p \< 0.05). E. Luciferase reporter assays with SKOV3 cells transfected with the mentioned reporter constructs of the PMEPA1 promoter, and treated as shown for 24. TGF-β treatment only activated the PMEPA Ti 850 reporter (p \< 0.05), while the combination of Flup and TGF-β activated both reporters (p \< 0.001). IO or Flup alone did not have any activating effect.

We then analyzed *PMEPA1* transcriptional activity, using two luciferase reporter constructs: the *PMEPA1* promoter fragment −1972*PMEPA1*-luc and PMEPA1 first intron pGL3ti-850 [@b0160]. In SKOV3 cells, *pGL3*ti-850 activity was stimulated by TGF-β treatment but not by fluprostenol alone, although it showed a strong synergistic activity with TGF-β. On the other hand, −1972*PMEPA1-luc* was only activated by the combination of fluprostenol and TGF-β ([Figure 2](#f0010){ref-type="fig"}E). These results would indicate that SMADs and NFAT co-operatively stimulate PMEPA1 mRNA expression, while the PGF~2α~ induction of *PMEPA1* could be also partially due to *TGFB1* induction.

We searched the GTRD ChIP-seq data and identified multiple NFATc1 binding sites, Site IDs 24982307-11, in the promoter and the first intron regulatory region of *PMEPA1*. Interestingly, we found several SMAD-2, SMAD-3 binding sites adjacent to the NFATc1 ones ([Suppl. Figure S4](#s0105){ref-type="sec"}).

All the above suggest a co-operation of NFAT with SMADs for *PMEPA1* induction, pointing to is a positive feedback loop between PGF~2α~/NFAT and TGF-β for PMEPA1 expression. TGF-β induced *PMEPA1* expression can be further potentiated by the PGF~2α~/Ca^2+^/CaN pathway, both through its main promoter as by the first intron enhancer.

PMEPA1 overexpression in cancer cells enhances cell growth {#s0070}
----------------------------------------------------------

To investigate the biological effects of PMEPA1 in tumor cells, we generated ovarian cancer cell lines (Skov3, OVCAR8, A2780 and TOV112D), stably overexpressing PMEPA1 and compared them with control cells carrying the empty vector (EV). Additionally, 5 PMEPA1 knockdown SKOV3-Luc cell lines were generated. Knockdown or overexpression were confirmed by RT-qPCR, WB and immunocytochemistry of thin layer preparations ([Suppl. Figure S5](#s0105){ref-type="sec"}). Interestingly, SKOV3 -cells had a higher proliferative rate than SKOV3-EV cells ([Figure 3](#f0015){ref-type="fig"}A). Similar results were obtained in PMEPA1 overexpressing A2780 and TOV112D ([Figure 3](#f0015){ref-type="fig"}B). PCNA protein levels increased accordingly, in agreement to this increased proliferation rate ([Figure 4](#f0020){ref-type="fig"}B). However, no difference in growth was observed in OVCAR8 cells (not shown). In contrast, proliferation rates of PMEPA1 knockdown cells were much lower compared to scrambled (SCR) control cells ([Figure 3](#f0015){ref-type="fig"}A). Anchorage independent survival revealed that PMEPA1 overexpressing cells survived better and formed bigger clusters that grew faster than EV cells ([Figure 3](#f0015){ref-type="fig"}C and D).Figure 3PMEPA1 overexpression in ovarian cancer cells enhances cell proliferation. A. Cell proliferation of 2 PMEPA1 overexpressing clonal SKOVE3 cell lines (*left panel*) and 5 knockdown (right panel) SKOV3 cell lines was estimated by cell counting using a hemocytometer. Average ± SEM are shown, n = 5. Growth curves were significantly different, p = 0.025 for overexpressing vs control and P \< 0.001 for knockdown vs SCR. These results were also confirmed by crystal violet stain quantification of SKOV3 (not shown), A2780 and TOV112D EV and PMEPA cells (B). C. Anchorage independent growth assays were performed with PMEPA1 overexpressing and control A2780 and SKOV3 cells that were monitored by light microscopy. Representative photos of the cells at 72 h after seeding are shown. Bars: 50 µm. D. Cell survival and proliferation in the assays in (C) was estimated at 96 h after plating by Alamar blue assay. Stain reduction quantification is shown for A2780 and Skov3Luc. Average ± SEM are shown, n = 3.Figure 4PMEPA1 overexpression favors a partially epithelial phenotype. A. Light microscopy images of SKOV3 and TOV112D -EV and --PMEPA1 cells in culture. Bars: 50 µm. B. WB for the indicated proteins in SKOV3, A2780 and TOV112D -PMEPA1 and -EV cells. C. Immunofluorescence for β-catenin of SKOV3-PMEPA1 and SKOV3-EV (EV) cells. Cells were treated with 5 ng/ml of TGF-β or combination of 10 µg/ml of recombinant Latency Associated Peptide (LAP-TGF-β) and 5 ng/ml of TGF-β for 24 h. Arrows indicate β-catenin localization in cell-cell contacts. D. WB to detect the indicated proteins in nuclear, membrane and cytoplasmic extracts of the SKOV3-lucD6 EV and SKOV3-PMEPA1 cells. E. qRT-PCR analysis of relative mRNA levels of *PMEPA1* and *CDH1* (E-cadherin) in SKOV3-EV and PMEPA1 overexpressing cells. F. qRT-PCR analysis of relative mRNA levels of *ZEB1, VIM, SNAI1* and *SNAI2* (coding for Zinc Finger E-Box Binding Homeobox 1, vimentin, SNAIL and SLUG respectively) in SKOV3-EV and PMEPA1 overexpressing cells.

PMEPA1 overexpression favors a partially epithelial phenotype {#s0075}
-------------------------------------------------------------

SKOV3 ovarian cells have been classified as "intermediate mesenchymal phenotype cells" [@b0165], in agreement with the fibroblast-like morphology the cells have in culture, and TOV112D and A2780 as mesenchymal whereas OVCAR8 cells are classified as epithelial. Once SKOV3 cells were transduced with the PMEPA1 expression vector, morphological changes began to be noticeable towards a more epithelial phenotype ([Figure 4](#f0020){ref-type="fig"}A). We observed similar changes to an epithelial phenotype in A2780 and TOV112D upon PMEPA1 transfection while but no changes in transduced already epithelial OVCAR8 cells. The intercellular junction E-cadherin expression was higher in PMEPA1 overexpressing cells ([Figure 4](#f0020){ref-type="fig"}B). This is in agreement with our finding that most ovarian tumors tested express both PMEPA1 and E-cadherin ([Figure 1](#f0005){ref-type="fig"}) and supported by the fact that *CDH1* is 40-fold more expressed in ovarian tumors as compared to normal ovarian tissue ([Suppl. Figure S7](#s0105){ref-type="sec"}).

The interaction between the E-cadherin and the WNT signaling pathway member leads to the retention of β-catenin in the cell membrane proximity [@b0170]. Thus, we next studied β-catenin protein subcellular localization in PMEPA1 overexpressing cells. β-catenin localized both in the cytoplasm and nucleus of SKOV3-EV cells, while in PMEPA1 overexpressing cells it had a perinuclear localization as well as in cell-cell contacts, where E-cadherin is localized ([Figure 4](#f0020){ref-type="fig"}C, D). As expected, TGF-β treatment induced translocation of β-catenin to the nucleus in SKOV3 cells, while this effect was absent when PMEPA1 was overexpressed ([Figure 4](#f0020){ref-type="fig"}C, D). Both the mesenchymal phenotype and β-catenin dissociation from the membrane of SKOV3 cells could be due to autocrine or paracrine TGF-β signaling, since a TGF-β blocking antibody ([Figure 4](#f0020){ref-type="fig"}C) or the LY2109761 TGFβRI inhibitor (not shown) also caused β-catenin membrane localization and a change to epithelial-like morphology. Surprisingly, E-cadherin expression was not affected by TGF-β treatment in PMEPA1 cells ([Figure 4](#f0020){ref-type="fig"}D). On the other hand, PMEPA1 overexpression caused an 8-fold induction in SKOV3 cells. This fact was not contrary to the strong induction of ZEB1 and Vimentin mRNA in PMEPA1 overexpressing cells, while SNAI1 and 2 mRNA levels do not vary. In the same sense, we found that PMEPA1 mRNA levels positively correlated with the levels of two ovarian cancer cell EMT signatures as calculated using the TCGA Ovarian Cancer data ([Suppl. Figure 9](#s0105){ref-type="sec"}). These results indicate that PMEPA1 overexpression can revert downregulation of E-cadherin in ovarian cancer cells and decrease nuclear β-catenin by TGF-β.

The relationship between PMEPA1, E-cadherin and β-catenin*,* is also supported by the finding that biopsies with high PMEPA1 levels, also express E-cadherin and β-catenin. β-catenin was in most cases detected in the plasma membrane and not nuclear ([Figure 1](#f0005){ref-type="fig"}). These results support *in vitro* experiments, indicating that PMEPA1 high expression coincides with E-cadherin expression and blocks β-catenin nuclear translocation in ovary patient's tumors.

PMEPA1 overexpression affects the TGF-β signaling pathway {#s0080}
---------------------------------------------------------

Increased phosphorylation of SMAD1/5/8 and SMAD2/3 was observed in PMEPA1 overexpressing un-stimulated cells while the fold increase in SMAD phosphorylation after TGF-β treatment was less pronounced in the case of SKOV3-PMEPA1 cells ([Figure 5](#f0025){ref-type="fig"}A). On the other hand, we detected high levels of SMAD2/3 and P-SMAD2/3 proteins in SKOV3-shPMEPA1 compared to SCR and the opposite situation in the case of p-SMAD1/5/8, observing lower phosphorylation levels in knockdown cells as compared to SCR ([Figure 5](#f0025){ref-type="fig"}B. For quantifications of the blots please see [Suppl. Figure S8](#s0105){ref-type="sec"}). Interestingly, reduced levels of SMAD2/3 in nuclear extracts were found in SKOV3-PMEPA1 cells, while the membrane bound SMAD2/3 increased ([Figure 5](#f0025){ref-type="fig"}C). Besides, we tested if PMEPA1 affected SMAD-dependent transcription of TGF-β-target genes. PMEPA1 overexpression decreased EDN1 and CDKN1A mRNA levels ([Figure 5](#f0025){ref-type="fig"}D), while its knockdown showed a tendency to increase SERPINE1, EDN1 and CDKN1A ([Figure 5](#f0025){ref-type="fig"}E). These results indicate that PMEPA1 can modulate the TGF-β pathway output in ovarian cancer cells.Figure 5PMEPA1 overexpression affects the TGFβ signaling pathway. SMAD1/5/8 and SMAD2/3 phosphorylation state as detected by WB in overexpressing (A) and knockdown (B) SKOV3 cells and their appropriated controls treated or not with 5 ng/ml TGF-β for 1 h. C. WB for SMAD2/3 protein levels in SKOV3-EV and -PMEPA1 cells nuclear, membrane and soluble extracts. Relative SERPINE1, EDN1 and CDKN1A (coding for PAI-1, Endothelin and p21^waf1^ respectively) mRNA levels in PMEPA1 overexpressing (D) and knockdown (E) SKOV3 cells and their corresponding controls. \*: p \< 0.05.

PMEPA1 promotes tumor growth in vivo {#s0085}
------------------------------------

Finally, to confirm that PMEPA1 promotes ovarian tumor growth, we tested PMEPA1 overexpressing or knockdown cell lines growth in mice ([Figure 6](#f0030){ref-type="fig"}). We used several xenograft mouse models to address different aspects of ovarian cancer growth and metastasis. In the case of subcutaneous xenografts, SKOV3-PMEPA1 tumor volume growth was much higher compared to SKOV-EV derived tumors that only became palpable around day 55 ([Figure 6](#f0030){ref-type="fig"}A). Monitoring tumor bioluminescence we found a growth advantage of SKOV3-PMEPA1 over SKOV3-EV xenografts from the beginning of the experiment ([Figure 6](#f0030){ref-type="fig"}B). At the end of the experiment, we extracted tumors to corroborate the mentioned results ([Suppl. Figure 10](#s0105){ref-type="sec"}). SKOV3-EV derived tumors were smaller; in some cases, we were not able to isolate a tumor mass, although we could detect bioluminescent signal. We confirmed these results, performing a similar experiment, of subcutaneous injection of TOV112D and A2780 control and PMEPA1 overexpressing cells, in the more permissive R2G2 mice. In the case of TOV112D cells, PMEPA1 overexpression duplicated tumor initiation rates comparing to EV cells, PMEPA1 tumors grew faster, reaching maximum allowed size at least a month earlier than the EV ones ([Suppl. Figure 11](#s0105){ref-type="sec"}). On the other hand, only A2780-PMEPA1 cells, but not the EV, presented detectable growing tumors during a 15-week monitoring period ([Suppl. Figure 11](#s0105){ref-type="sec"}).Figure 6PMEPA1 promotes tumor growth *in vivo*. A. Subcutaneous xenograft Skov3Luc-EV and -PMEPA1 tumor volume, measured once a week, using a digital caliper. EV derived tumors became palpable around the 8th week post inoculation. B. Bioluminescence Imaging (BLI) quantification of the xenografts in (A). C. Growth of intraperitoneal injected cells was measure by bioluminescence quantification with IVIS Lumina Imaging system. Orthotopic tumor xenografts growth estimation through bioluminescence quantification of PMEPA1 overexpressing (D) and knockdown (E) SKOV3Luc derived cell lines. Tumors were removed at 35 dpi, but BLI monitorization continued until day 63 in both experiments. F. IHC of tumors derived from *PMEPA1* overexpressing or knockdown SKOV3 cells, stained for the indicated proteins. Magnification x400. B,C,D: Results are represented as logarithmic scale of Photons/sec/cm^2^/sr means ± SEM.

To investigate the effects of PMEPA1 on tumor cell peritoneal dissemination, we injected intraperitoneally two SKOV3-PMEPA1 cell lines and SKOV3-EV cells. SKOV3-PMEPA1 xenografts had an important proliferative advantage, even more remarkable than in the subcutaneous experiments ([Figure 6](#f0030){ref-type="fig"}C). To search for internal organ invasion, we extracted some organs (stomach, intestine, spleen, kidneys and pancreas) and peritoneal membrane. In mice that harbored SKOV3-PMEPA1, bio-luminescent signal could be detected in several internal organs, while in SKOV3-EV mice, all organs were negative ([Suppl. Figure S9](#s0105){ref-type="sec"}). Besides, peritoneal walls of SKOV3-PMEPA1 xenografts show localized luminescence signals corresponding to established metastases ([Suppl. Figure S12](#s0105){ref-type="sec"}). These results suggest that intraperitoneal dissemination and metastasis is facilitated by PMEPA1 overexpression.

Finally, to recapitulate all the steps of ovarian cancer growth, dissemination and metastasis, cells were injected orthotopically into the ovary. SKOV3-PMEPA1 xenografts showed a strong growth advantage compared with SKOV3-EV, which could hardly form intra-ovary tumors ([Figure 6](#f0030){ref-type="fig"}D). More importantly, shPMEPA1 SKOV3 grew less, reaching lower BLI signal levels than SCR and much less than SKOV3-PMEPA1 xenografts ([Figure 6](#f0030){ref-type="fig"}E) indicating that even the low PMEPA1 levels of control cells are important for tumor growth. Thus, the difference between overexpressing and silencing PMEPA1 in SKOV3 cells resulted in about 20,000 fold in growth as measured by bioluminescence intensity.

To investigate the potential for these cells to develop metastasis, ovaries were removed on day 35 (red arrow) and mice were monitored for bioluminescence, indicating metastatic tumor growth. A week after the operation, bioluminescence could be detected again, indicating cells had already metastasized ([Figure 6](#f0030){ref-type="fig"}E). Thus, PMEPA1 gives a clear advantage to ovarian tumor cells to adapt and grow in all the tested conditions. These in vivo results and the PMEPA1 expression in patient high-grade tumors strongly suggest that PMEPA1 could be an accurate biomarker of prognosis in ovarian cancer.

Discussion {#s0090}
==========

PGF~2α~ has only recently been associated with tumor progression in colorectal [@b0025], [@b0175] and endometrial cancer [@b0180]. Since it is naturally produced in the ovary and capable to produce strong effects on the epithelium [@b0185] it would be logical to assume that it may have an important role also in ovarian cancer. Remarkably, although *PTGFR* levels are lower in ovarian tumors than in normal ovary, ovarian cancer patients with higher *PTGFR* mRNA levels exhibit lower survival probabilities than patients with lower PTGFR levels ([Suppl. Figure S13](#s0105){ref-type="sec"}). These findings make PTGFR a potentially interesting pharmacological target against ovarian cancer dissemination and metastasis.

The TGF-β superfamily plays an important role in ovarian function and pathogenesis [@b0190] while, remarkably, mutations in genes of this pathway are infrequent in ovarian cancer [@b0195]. Importantly, we observed *TGFB1* up-regulation in ovarian cancer. Others and we have demonstrated the importance of TGF-β in ovarian cancer cell dissemination and metastasis in the peritoneal cavity [@b0145], [@b0200], the primary metastatic site of this type of cancer [@b0205]. We first describe here the induction of TGFB1 by PGF~2α~ in cancer cells and our observation supports one earlier publication observing this induction in healthy bovine *corpus luteum* [@b0210]. Not surprisingly, we found a strong correlation between the expression of TGFB1 and all the components of the COX2-PGF~2α~-PTGFR-NFAT pathway tested. We are the first to report the association of Ca^2+^/Calcineurin/NFAT signaling with the transcriptional control of *TGFB1*. We thus offer data that show the convergence between two pathways of great importance in cancer progression. COX2 products, such as PGF~2α~, are able to induce TGFB1 transcription. This could further contribute to explain many of the effects of COX2 and PGs in the tumor setting, such as EMT [@b0215], metastasis and immune evasion [@b0220].

As mentioned, ovarian tumors rarely acquire mutations in the TGF-β pathway, although this cytokine is up-regulated in tumors over normal tissue. PMEPA1, already proposed to be a "molecular switch that converts TGF-β, normally a tumor suppressor, to a tumor promoter" [@b0060] could be the responsible for this inconsistency. Indeed, we found PMEPA1 elevated in most ovarian tumors, its expression correlating with that of TGFB1. Remarkably, PMEPA1 is induced also by PGF~2α~/NFAT axis, as by TGF-β, reaching a synergistic effect when activating both pathways. PMEPA1 overexpression increased tumor cell growth both *in vitro* and *in vivo*, as we demonstrate using different cell lines and *in vivo* tumor models, while its knockdown had the opposite effect. Thus, silencing PMEPA1 resulted in reduced tumor growth *in vivo*. Our results also suggest that intraperitoneal dissemination and metastasis is strongly reduced by PMEPA1 knockdown. Given the fact that intracellular TGF-β signaling moderately decreased, switching from SMAD2/3 to SMAD1/5/8, we believe that PMEPA1 expressing cells are able to affect the tumor stroma without suffering the negative effects TGF-β could induce. Our data on the pro-tumoral effect of PMEPA1 in ovarian cancer are also supported by the fact that high PMEPA1 mRNA levels are associated with lower survival rate of ovarian cancer patients.

It has been proposed that mutations or loss of p53 modify TGF-β action in ovarian cancer [@b0225], although this seems to be independent to the effect observed with PMEPA1, since this was found in both p53 wt (A2780) and null cell lines (SKOV3).

PMEPA1 overexpression altered cell morphology, prompting a more epithelial phenotype, although TGF-β production by the cells is increased. This altered morphology could be due to the up-regulation of E-cadherin we observed. Indeed, PMEPA1 was able to elevate functional E-cadherin levels and thus concentrate part of the β-catenin in the intercellular junctions, while other epithelial markers failed to be induced. We demonstrate that β-catenin remains in a cytoplasmic and/or membrane localization in a PMEPA1 dependent manner, in agreement with a very recent publication by Amalia et al., showing how PMEPA1 inhibited Wnt signaling through β-catenin stability and nuclear localization regulation [@b0230]. E-cadherin can be degraded or downregulated upon different stimuli, as TGF-β [@b0235], and thus lose association with β-catenin, that could translocate to the nucleus. SKOV3-EV cells show β-catenin nuclear localization probably due to basal autocrine TGF-β signaling [@b0145] and absence of membrane E-cadherin. The effect of PMEPA may be explained, not only by a decrease in the suppression of *CDH1* by TGF-β, but potentially a decrease of E-cadherin endocytosis and degradation. This is also supported by the fact that we found the same epithelial morphology and β-catenin cytoplasmic localization when we treated cells with a latency-associated-peptide, inhibiting TGF-β or using a TGFβR inhibitor. Another plausible explanation to this phenomenon could be the fact that β-catenin can depend on SMAD3 to translocate to the nucleus [@b0240]. Indeed, we also found that the overexpression of PMEPA1 reduced nuclear SMAD2/3, as already described in other cell systems [@b0055], [@b0060], [@b0120].

It has been already shown that E-cadherin expression can have a positive effect on tumor aggressiveness and metastasis [@b0245], which would perfectly agree with our results. Moreover, we observed that PMEPA1 overexpressing cells, not only had elevated growth capacity on substrate, but also anchorage independent growth, in accordance with previous reports attributing this role to E-cadherin [@b0250].

It is well established that E-cadherin expression and decreased cell mobility are common epithelial cell characteristics, while upregulation of N-cadherin, vimentin and zinc-finger domain proteins (SNAI1/SNAIL, SNAI2/SLUG), among others, are often linked to a mesenchymal-like phenotype [@b0255]. A notable case is the ovarian surface epithelial (OSE) cells, in which overexpression of E-cadherin induces a number of epithelial characteristics and markers associated with malignant transformation and tumor progression [@b0260]. Remarkably, both primary and metastatic ovarian carcinomas express E-cadherin, in contrast to normal ovarian surface epithelium, which rarely expresses E-cadherin [@b0265], [@b0270]. Further work should be done to elucidate the detailed mechanisms through which PMEPA1 upregulates or avoids downregulation of E-cadherin and if these depend exclusively on TGFβR signaling. We believe this E-cadherin elevation is not due to the lack of *CDH1* suppression, since we were only able to overexpress E-cadherin in PMEPA1-overexpressing but not in EV cells (data not shown). On the other hand, although elevated E-cadherin expression was observed because of PMEPA1 expression, cells also induced Vimentin and ZEB1 at the same time. Moreover, *in silico* analysis of the TCGA Ovarian cancer cohort showed that PMEPA1 mRNA levels correlate both with CDH1 levels as well as with EMT gene signatures scores. This indicates that PMEPA1 overexpressing cells could take advantage of both epithelial and mesenchymal characteristics, which could be an explanation of the aggressiveness of these cells. Interestingly, PMEPA1 effects on growth can be observed only in ovarian carcinoma cell lines with mesenchymal or intermediate mesenchymal phenotype but not in OVCAR8 cells that are classified as epithelial. This supports idea that the effects of PMEPA1 in favoring an epithelial phenotype are linked to those on growth advantages.

Using a high-grade ovarian tumor patient cohort, we found strong PMEPA1 expression in most tumors, perfectly correlating with E-cadherin and β-catenin high expression. Bigger cohorts, including lower grade primary tumor biopsies should be used to confirm if PMEPA1 is linked to metastasis and its prognostic value. All the above could indicate that PMEPA1 can tweak TGF-β signaling while making tumor cells produce more, upregulate E-cadherin protein levels and reduce β-catenin nuclear localization, thus increasing cell plasticity and proliferation.
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